Iovance Stock Soars 21.2% on Amtagvi Approval

On August 19, 2025, Iovance's stock surged by 21.2% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Iovance Biotherapeutics has achieved a major breakthrough with the approval of its Amtagvi® (lifileucel) by Health Canada. This approval makes Amtagvi the first T cell therapy for a solid tumor cancer and the first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy. This milestone is expected to bolster investor confidence in the company's innovative approach to cancer treatment.

The approval of Amtagvi by Health Canada is a testament to Iovance's commitment to developing groundbreaking therapies. This achievement not only expands the company's market reach but also positions it as a leader in the field of cancer immunotherapy. The positive regulatory decision is likely to drive further interest in Iovance's stock, as investors anticipate the potential for increased revenue and market share.